Sotyktu (deucravacitinib) for treatment of adults with active psoriatic arthritis (PsA). Sotyktu is an oral, selective ...
Key Summary The transition from psoriasis to psoriatic arthritis (PsA) is driven by several modifiable risk factors, ...
The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.
Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...
In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.
The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...
At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...
Decluttering Mom on MSN
Woman books manicure at nail salon but says infection led to six surgeries and a warning to stay away
A routine trip to the nail salon turned into a nightmare for Claudia Ruffin, a 27-year-old Sydney woman who contracted a bacterial infection that led to sepsis from what should have been a simple ...
One reviewer even found relief after struggling with foot fungus for 22 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results